A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)
The purpose of this study is to determine the long term safety of patients with refractory solid tumors who have experienced clinical benefit after at least 6 cycles of treatment in BMS Protocol CA124-001 or CA124-002.
Pediatric Solid Tumors
DRUG: Carboplatin|DRUG: Irinotecan|DRUG: Irinotecan
Assessment of safety and tolerability, 22 months
Assessment of duration of clinical benefit per CT or MRI, steroid use and neuropathy assessment, Every other cycle for 22 months
The purpose of this study is to determine the long term safety of patients with refractory solid tumors who have experienced clinical benefit after at least 6 cycles of treatment in BMS Protocol CA124-001 or CA124-002.